Leadership Overview
Sarepta Therapeutics has 9 executives leading key functions including strategy, information technology, medical operations, regulatory affairs, operations, corporate planning, human resources, and research development.
Focused on precision genetic medicine, Sarepta Therapeutics advances life-changing therapies for rare diseases through a robust pipeline of gene therapy and RNA-targeted treatments.
Focused on precision genetic medicine, Sarepta Therapeutics advances life-changing therapies for rare diseases through a robust pipeline of gene therapy and RNA-targeted treatments.
Leadership Roles at Sarepta Therapeutics
Michael Severino - Chief Executive Officer
Michael Severino, the Chief Executive Officer at Sarepta Therapeutics, directs the overarching strategic vision for the development of precision genetic medicines. Severino manages the transition of research programs into commercial-stage assets, ensuring the company maintains a competitive edge in the neuromuscular disorder market. By aligning the board of directors with long-term growth objectives, the Chief Executive Officer drives the expansion of the Precision Genetic Medicine Engine across North America, Europe, and Asia. Michael Severino oversees the integration of gene therapy and RNA-targeted platforms to address unmet patient needs. This leadership role involves constant evaluation of the global pipeline to maximize therapeutic impact. Through rigorous oversight of clinical milestones and regulatory pathways, Severino secures the financial and operational health of the organization. The Chief Executive Officer champions innovation, ensuring the company remains a leader in the biopharmaceutical sector while delivering value to stakeholders and patients alike.
Ian Estepan - President & Chief Operating Officer
Ian Estepan, the President & Chief Operating Officer at Sarepta Therapeutics, directs the day-to-day business operations and commercial execution of the company's genetic medicine portfolio. Estepan manages the scaling of manufacturing and supply chain capabilities to support the global distribution of approved treatments. By overseeing the operational integration of the Precision Genetic Medicine Engine, the President & Chief Operating Officer ensures that the company meets the demands of the neuromuscular disorder market. Ian Estepan drives the strategic initiatives that expand the company's footprint across North America and international territories. This role involves close coordination with the executive team to optimize resource allocation and operational efficiency. Through the management of commercial-stage assets, the President & Chief Operating Officer supports the company's mission to deliver life-changing therapies. Estepan maintains a focus on operational excellence, ensuring that the organization remains agile and responsive to the evolving needs of the rare disease community.
Louise Rodino-Klapac - President, Research Development & Technical Operations
Louise Rodino-Klapac, the President, Research Development & Technical Operations at Sarepta Therapeutics, directs the scientific discovery and technical manufacturing processes for the company's genetic medicine platforms. Rodino-Klapac manages the research teams responsible for the development of gene therapy, RNA-targeted therapeutics, and gene editing modalities. By overseeing the transition from laboratory research to technical operations, the President, Research Development & Technical Operations ensures the scalability and quality of the company's pipeline. Louise Rodino-Klapac drives the innovation required to address neuromuscular and central nervous system disorders through precision genetic medicine. This role involves close collaboration with regulatory and clinical teams to advance programs through the development lifecycle. Through the management of technical operations, the President, Research Development & Technical Operations secures the company's ability to deliver high-quality treatments to patients globally. Rodino-Klapac maintains a focus on scientific rigor, ensuring that the organization remains at the forefront of biopharmaceutical innovation.
Bill Thornton - Chief Information Officer
Bill Thornton, the Chief Information Officer at Sarepta Therapeutics, architects the digital infrastructure necessary to support complex biopharmaceutical research and global commercial operations. Thornton manages the data systems that house critical information regarding gene therapy and RNA-targeted clinical trials. By implementing secure, scalable technology solutions, the Chief Information Officer ensures seamless collaboration across international research sites. Bill Thornton optimizes the digital landscape to accelerate the discovery of precision genetic medicines for rare diseases. This role involves protecting sensitive intellectual property while providing the analytical tools required for data-driven decision-making within the executive team. Thornton maintains the integrity of the company's technological framework, supporting the rapid development of treatments for Duchenne muscular dystrophy. Through the deployment of advanced computing resources, the Chief Information Officer enables the organization to maintain its position as a global leader in the competitive landscape of genetic medicine.
Kirsten M. - Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff
Kirsten M., the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff at Sarepta Therapeutics, coordinates the execution of medical strategies across the global portfolio. Kirsten M. manages the operational workflows that bridge clinical research and commercial medical affairs, ensuring alignment with the company's mission to treat rare diseases. By streamlining program management processes, the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff facilitates the efficient delivery of precision genetic medicines to patients worldwide. This role involves close collaboration with cross-functional teams to monitor the progress of neuromuscular and central nervous system disorder programs. Kirsten M. drives the operational excellence required to support the company's broad pipeline of gene therapy and RNA-targeted therapeutics. Through meticulous planning and resource allocation, the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff ensures that medical objectives remain synchronized with the broader corporate strategy.
Zohal Ghiaszada - Senior Director, Chief of Staff To Chief Medical and Regulatory Officer
Zohal Ghiaszada, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer at Sarepta Therapeutics, manages the strategic priorities and operational flow for the medical and regulatory divisions. Ghiaszada facilitates communication between the executive leadership and the teams responsible for securing FDA approvals for genetic medicines. By overseeing the coordination of complex regulatory filings, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer ensures that the company meets critical milestones for Duchenne muscular dystrophy treatments. Zohal Ghiaszada drives the alignment of medical affairs with the company's global commercial goals. This role involves managing the internal processes that support the development of gene editing modalities. Through the effective management of departmental resources, the Senior Director, Chief of Staff To Chief Medical and Regulatory Officer enables the organization to navigate the intricate regulatory landscape while maintaining a focus on patient safety and therapeutic efficacy.
William Tilton - Senior VP, Corporate Strategy & Chief of Staff
William Tilton, the Senior VP, Corporate Strategy & Chief of Staff at Sarepta Therapeutics, architects the long-term planning and strategic initiatives that define the company's market position. Tilton manages the alignment of corporate goals with the development of the gene therapy and RNA-targeted pipeline. By analyzing market trends and competitive dynamics, the Senior VP, Corporate Strategy & Chief of Staff provides the executive team with the insights necessary to prioritize research and commercial investments. William Tilton drives the execution of strategic partnerships and business development opportunities that enhance the company's portfolio of precision genetic medicines. This role involves coordinating the activities of the executive office to ensure that all departments remain focused on the core mission of treating rare diseases. Through the development of robust strategic frameworks, the Senior VP, Corporate Strategy & Chief of Staff supports the company's growth and long-term sustainability in the global biopharmaceutical industry.
Kirsten Meisterling - Senior Director, Chief of Staff To Senior Vice President, Medical Affairs
Kirsten Meisterling, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs at Sarepta Therapeutics, manages the operational priorities and strategic initiatives within the medical affairs department. Meisterling coordinates the efforts of teams focused on the clinical communication and medical education of the company's genetic medicine portfolio. By facilitating the flow of information between medical leadership and external stakeholders, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs ensures that the clinical value of the company's treatments is clearly articulated. Kirsten Meisterling drives the internal processes that support the launch and ongoing medical support of therapies for Duchenne muscular dystrophy. This role involves managing the administrative and strategic functions that allow the medical affairs team to operate effectively on a global scale. Through the coordination of departmental resources, the Senior Director, Chief of Staff To Senior Vice President, Medical Affairs supports the company's commitment to patient-centered care.
Alison Nasisi - Executive Vice President & Chief People Officer
Alison Nasisi, the Executive Vice President & Chief People Officer at Sarepta Therapeutics, directs the human capital strategy and organizational development initiatives. Nasisi manages the recruitment, retention, and professional growth of the talent required to advance the company's complex gene therapy and RNA-targeted programs. By fostering a culture of innovation and collaboration, the Executive Vice President & Chief People Officer ensures that the organization attracts the expertise necessary to lead in the field of precision genetic medicine. Alison Nasisi drives the implementation of programs that support employee engagement and diversity across the company's global locations. This role involves aligning the workforce with the company's mission to address rare diseases through scientific excellence. Through the development of robust talent management systems, the Executive Vice President & Chief People Officer supports the company's ability to scale its operations and maintain its position as a top-tier biopharmaceutical employer.
Explore Leadership Teams in Manufacturing
Roche is a global pioneer in pharmaceuticals and diagnostics, dedicated to advancing science to improve people's lives through innovative healthcare solutions. The Swiss-based company operates through two primary divisions: Pharmaceuticals and Diagnostics, making it one of the few healthcare companies with leading positions in both areas. Roche's pharmaceutical division focuses on developing and manufacturing prescription medicines across major therapeutic areas including oncology, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. The diagnostics division provides a comprehensive range of products and services for early detection, prevention, diagnosis, and management of diseases, spanning laboratory diagnostics, tissue diagnostics, and diabetes care. Roche is committed to personalized healthcare, pioneering the development of targeted therapies and companion diagnostics that enable treatment decisions tailored to individual patients. The company invests heavily in research and development, maintaining a robust pipeline of innovative medicines and diagnostic solutions while collaborating with academic institutions, biotechnology companies, and healthcare partners worldwide. Headquartered in Basel, Switzerland, Roche operates globally with a presence in numerous countries, employing a diverse workforce of scientists, researchers, healthcare professionals, and business experts dedicated to transforming patient care and making a meaningful difference in the fight against serious diseases.
Company Leadership TH
AH
CB
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Company Leadership
CC
SR
USV Private Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. USV Limited was established in 1961.
Company Leadership AV
SY
RC
Founded in 1995, The Ritedose Corporation is a manufacturing and packaging facility, located in Columbia, SC.
Company Leadership
DM
JM
Frequently Asked Questions Regarding Sarepta Therapeutics Top Executives and Leadership Team
Unlock more people and company data
